Canaccord Genuity Assumes Coverage on Vertex (VRTX) at Hold; Shares Fairly Valued

July 6, 2011 8:30 AM EDT
Get Alerts VRTX Hot Sheet
Price: $515.55 +1.94%

Rating Summary:
    38 Buy, 7 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 12 | Down: 23 | New: 22
Join SI Premium – FREE
Canaccord Genuity assumes coverage on Vertex (NASDAQ: VRTX) with a Hold. PT $48.

Canaccord analyst, Dr. George Farmer, says, "Supported by early script data trends and a clinical benefit profile providing higher HCV cure rates with shorter treatment duration than previous standard-of-care, we see high expectations for a successful INCIVEK (telaprevir) launch already reflected in VRTX shares. An overwhelmingly large patient target population drives our 2011 and 2012 U.S. sales estimates of $601M and $2.0B, feeding our total revenue estimates of $754M and $2.3B vs. consensus of $724M and $2.2B."

For more ratings news on Vertex click here and for the rating history of Vertex click here.

Shares of Vertex closed at $52.19 yesterday.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

New Coverage